Medication info

Glyromept Tablet 5/1000 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
IYUN Pharmaceuticals Co., Ltd.
Appearance
Yellow, oval-shaped, biconvex film-coated tablet with a brownish tint
Packaging
10 tablets/box [(10 tablets/PTP×1)], 60 tablets/box [(10 tablets/PTP×6)], 60 tablets/bottle
Approval status
Active

MFDS item code 202201746 · Approved 2022.04.29

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and their existing metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their existing doses of empagliflozin and metformin. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take a double dose at one time; skip the missed dose in this case. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). Elderly patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
IYUN Pharmaceuticals Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • impaired glycemic control
  • cardiovascular disease
  • cardiovascular events
View approved original text

This medication is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by combining empagliflozin and metformin. It is effective for managing blood sugar, especially in type 2 diabetes patients with cardiovascular disease. For related clinical information, it is best to refer to professional materials. This medication helps improve blood sugar control.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and their existing metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their existing doses of empagliflozin and metformin. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Drug Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take a double dose at one time; skip the missed dose in this case. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). Elderly patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is used for diabetes treatment and contains two components that lower blood sugar. This medication can cause a rare but fatal side effect known as lactic acidosis, so patients with poor kidney function or severe infections, dehydration, or heart problems should not use it. Caution is necessary when taken with insulin or other diabetes medications as there is a risk of hypoglycemia. Patients with moderate to severe renal impairment, liver dysfunction, and pregnant or nursing women should not take this medication. Before and after surgery or examinations using iodine contrast agents, the use of this medication should be temporarily discontinued, and it should be resumed only after checking kidney function. This medication may increase the risk of urinary tract infections and genital infections, so if symptoms of infection appear, medical consultation should be sought immediately. Vitamin B12 levels may decrease, so it is advisable to regularly check vitamin B12 levels during prolonged use. Alcohol consumption can increase the risk of lactic acidosis, so excessive drinking should be avoided while taking this medication. Elderly patients are at higher risk of fluid loss and decreased kidney function, necessitating regular monitoring of kidney function and fluid status. If symptoms such as sudden muscle pain, weakness, difficulty breathing, abdominal pain, nausea, or vomiting occur while taking this medication, inform a doctor immediately. Hypoglycemic symptoms may occur, so do not skip meals and take it regularly, and respond immediately if hypoglycemic symptoms are suspected. Furthermore, safety and effectiveness have not been established in children, and it is recommended that individuals under 18 do not take this medication. Lastly, this medication should be taken strictly according to a doctor's prescription and instructions, and it should not be stopped or the dose changed arbitrarily.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
Show 191 more
  • abnormal liver function tests
  • hepatitis
  • taste disturbance
  • itching
  • rash
  • urticaria
  • erythema multiforme
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
  • perineal necrosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • gastrointestinal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • salpingo-oophorectomy
  • vestibular neuritis
  • acute pyelonephritis
  • headache
  • sensory impairment
  • orthostatic dizziness
  • dizziness
  • amnesia
  • drowsiness
  • CNS-induced vertigo
  • fatigue
  • peripheral edema
  • facial edema
  • peripheral swelling
  • fever
  • facial swelling
  • chills
  • odd sensations
  • swelling
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • chest pain
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • hypertension
  • insomnia
  • anxiety
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • otalgia
  • orthostatic vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • upper respiratory tract infection
  • herpes zoster
  • diabetic foot
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • nummular eczema
  • miliaria
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • eye discomfort
  • ocular congestion
  • pathologic myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • traction retinal detachment
  • eyelid swelling
  • visual impairment
  • floaters
  • vitreous hemorrhage
  • nasal bleeding
  • asthma
  • exertional dyspnea
  • productive cough
  • allergic rhinitis
  • residual phlegm
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina pectoris
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • cervical inflammation
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • vaginal discharge
  • hypoglycemia
  • decreased appetite
  • obesity
  • hypernatremia
  • hyperlipidemia
  • dyslipidemia
  • hyperglycemia
  • weight gain
  • electrocardiogram abnormalities
  • decreased hemoglobin
  • increased hemoglobin
  • positive Helicobacter test
  • positive urine red blood cells
  • ureteral calculi
  • acute kidney injury
  • chronic kidney disease
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary tract pain
  • abnormal urine
  • benign ovarian tumor
  • bladder cancer
  • cholesteatoma
  • stomach cancer
  • leiomyoma
  • pancreatic adenocarcinoma
  • colorectal cancer
  • thyroid cancer
  • uterine leiomyoma
  • unstable angina
  • anxiety
  • depression
  • sleep disorder

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius (room temperature).

Appearance and packaging

Appearance

Yellow, oval-shaped, biconvex film-coated tablet with a brownish tint

Package unit

10 tablets/box [(10 tablets/PTP×1)], 60 tablets/box [(10 tablets/PTP×6)], 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.